Media Release 20 Nov 2017

Clearbridge Health and Nanostring Technologies partner to provide Prosigna Breast Cancer Prognostic Gene Signature Assay in Asia

Clearbridge Health will be the exclusive provider of Prosigna in Singapore, Malaysia, Indonesia and Philippines.

Clearbridge Health, a healthcare company with a focus on the delivery of precision medicine in Asia, and NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Clearbridge Health, through its subsidiary SAM Laboratory will become the first and exclusive provider of the Prosigna Breast Cancer Prognostic Gene Signature Assay to patients in Singapore, Malaysia, Indonesia, and the Philippines, as well as on a non-exclusive basis throughout Asia, pending applicable local regulatory approvals.

"We are very excited about bringing Prosigna to breast cancer patients in Asia," said Jeremy Yee, CEO of Clearbridge Health, "Nanostring is a leading genomics company, and we believe that providing Prosigna, the FDA approved breast cancer recurrence risk test, will enable clinicians to better inform their patients on treatment options. Breast cancer is a growing disease in Asia, and CBH is focused on addressing this clinical need by delivering molecular diagnostics to improve disease management and patient outcomes."

"We're excited to be working with Clearbridge Health to bring our Prosigna Breast Cancer Prognostic Gene Signature Assay to Southeast Asia through its lab, SAM Laboratory.", said Brad Gray, President and CEO of NanoString Technologies. "Clearbridge Health has been at the forefront of advancing personalized medicine in Singapore and throughout Asia, making them an ideal partner. This relationship exemplifies our vision of making breast cancer prognostic testing available at a local and regional level, thus ensuring clinicians and indicated patients have the best possible information when making treatment decisions."

About Clearbridge Health
CBH is a company with a focus on the delivery of precision medicine in Asia. CBH's business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnosis, provide insights to disease management, and tailor personalised prevention and timely treatment programme for patients. For more information, please visit us at www.clearbridgehealth.com.

About the Prosigna® Breast Cancer Prognostic Gene Signature Assay and nCounter® Dx Analysis System
The Prosigna Assay provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer. Based on the PAM50 gene signature initially discovered by Charles Perou, Ph.D. and colleagues, the Prosigna Assay is an *in vitro* diagnostic tool that utilizes gene expression data weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence of disease. The Prosigna Assay measures gene expression levels of RNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor tissue previously diagnosed as invasive breast carcinoma.

The Prosigna Assay requires minimal hands-on time and runs on NanoString's proprietary nCounter® Dx Analysis System, which offers a reproducible and cost-effective way to profile many genes simultaneously with high sensitivity and precision.

The nCounter Dx Analysis System is a highly automated and easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high precision multiplexed assays. The system is available in the multi-mode FLEX configuration, which is designed to meet the needs of high-complexity clinical laboratories seeking a single platform with the flexibility to run the Prosigna Breast Cancer Assay and, when operated in the "Life Sciences" mode, process translational research experiments and multiplexed assays developed by the laboratory.

In the United States, the Prosigna Assay is 510(k) cleared for use on the nCounter Dx Analysis System, and is available for diagnostic use when ordered by a physician. The Prosigna Assay has been CE-marked and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark, as well as Canada, Israel, Australia, New Zealand and Hong Kong. In the U.S., the Prosigna Assay is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care, either as:

(1) a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women with Hormone Receptor-Positive (HR+), lymph node-negative, Stage I or II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors or (2) a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women with Hormone Receptor-Positive (HR+), lymph node-positive (1-3 nodes), Stage II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. The device is not intended for patients with four or more positive nodes.

For more information, please visit www.prosigna.com.

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,650 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.

Contact:

Clearbridge Health
Andrew Wu
Chief Product Officer
andrew.wu@clearbridgehealth.com
Phone: +65 62510136

Nanostring Technologies
Douglas Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768